title: Augmentation of methamphetamine-induced behaviors in transgenic mice lacking the trace amine-associated receptor 1.
abstract: The trace amine-associated receptor 1 (TAAR1) is a G protein-coupled receptor that is functionally activated by amphetamine-based psychostimulants, including amphetamine, methamphetamine and MDMA. Previous studies have shown that in transgenic mice lacking the TAAR1 gene (TAAR1 knockout; KO) a single injection of amphetamine can produce enhanced behavioral responses compared to responses evoked in wild-type (WT) mice. Further, the psychostimulant effects of cocaine can be diminished by selective activation of TAAR1. These findings suggest that TAAR1 might be implicated in the rewarding properties of psychostimulants. To investigate the role of TAAR1 in the rewarding effects of drugs of abuse, the psychomotor stimulating effects of amphetamine and methamphetamine and the conditioned rewarding effects of methamphetamine and morphine were compared between WT and TAAR1 KO mice. In locomotor activity studies, both single and repeated exposure to d-amphetamine or methamphetamine generated significantly higher levels of total distance traveled in TAAR1 KO mice compared to WT mice. In conditioned place preference (CPP) studies, TAAR1 KO mice acquired methamphetamine-induced CPP earlier than WT mice and retained CPP longer during extinction training. In morphine-induced CPP, both WT and KO genotypes displayed similar levels of CPP. Results from locomotor activity studies suggest that TAAR1 may have a modulatory role in the behavioral sensitization to amphetamine-based psychostimulants. That methamphetamine-but not morphine-induced CPP was augmented in TAAR1 KO mice suggests a selective role of TAAR1 in the conditioned reinforcing effects of methamphetamine. Collectively, these findings provide support for a regulatory role of TAAR1 in methamphetamine signaling.
authors.affiliation: Division of Neuroscience, New England Primate Research Center, Harvard Medical School, Southborough, MA 01772, United States. cindy_achat-mendes@hms.harvard.edu
authors.forename: Cindy
authors.initials: C
authors.lastname: Achat-Mendes
authors.forename: Laurie J
authors.initials: LJ
authors.lastname: Lynch
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Sullivan
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Vallender
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Miller
mesh_terms: D000818:Animals; D003213:Conditioning, Psychological / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009043:Motor Activity / Q000187:drug effects*; D043562:Receptors, G-Protein-Coupled / Q000172:deficiency* / Q000235:genetics; D000095383:Trace Amine-Associated Receptors
chemical_list: D008694:Methamphetamine; D043562:Receptors, G-Protein-Coupled; D000095383:Trace Amine-Associated Receptors
references.citation: Neuropsychopharmacology. 2005 Jun;30(6):1128-37
references.pmid: 15688084
references.citation: Genes Brain Behav. 2007 Oct;6(7):628-39
references.pmid: 17212650
references.citation: Mol Pharmacol. 2001 Dec;60(6):1181-8
references.pmid: 11723224
references.citation: J Pharmacol Exp Ther. 2008 Mar;324(3):948-56
references.pmid: 18083911
references.citation: Eur J Pharmacol. 1983 Nov 25;95(3-4):311-4
references.pmid: 6686144
references.citation: J Neurosci. 2010 Mar 31;30(13):4676-86
references.pmid: 20357118
references.citation: Pharmacol Biochem Behav. 1977 Jun;6(6):689-96
references.pmid: 263551
references.citation: J Pharmacol Exp Ther. 2007 Apr;321(1):178-86
references.pmid: 17218486
references.citation: Rev Recent Clin Trials. 2007 Jan;2(1):3-19
references.pmid: 18473983
references.citation: Proc Natl Acad Sci U S A. 2011 May 17;108(20):8485-90
references.pmid: 21525407
references.citation: Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20081-6
references.pmid: 19892733
references.citation: Fed Proc. 1964 Jul-Aug;23:836-50
references.pmid: 14195468
references.citation: J Pharmacol Exp Ther. 2008 May;325(2):617-28
references.pmid: 18182557
references.citation: Pharmacol Biochem Behav. 1985 Jan;22(1):101-5
references.pmid: 2858106
references.citation: Psychopharmacology (Berl). 2003 Mar;166(3):249-57
references.pmid: 12589519
references.citation: Biochem Pharmacol. 2009 Nov 1;78(9):1095-104
references.pmid: 19482011
references.citation: J Pharmacol Exp Ther. 2007 Apr;321(1):116-27
references.pmid: 17234900
references.citation: Psychopharmacology (Berl). 2000 Dec;153(1):31-43
references.pmid: 11255927
references.citation: J Neurosci. 2009 May 13;29(19):6176-85
references.pmid: 19439595
references.citation: J Neurosci. 2006 Oct 25;26(43):11041-51
references.pmid: 17065446
references.citation: J Pharmacol Exp Ther. 2009 Jul;330(1):316-25
references.pmid: 19364908
references.citation: J Neurochem. 2011 Jan;116(2):164-76
references.pmid: 21073468
references.citation: J Pharmacol Exp Ther. 1983 Oct;227(1):229-37
references.pmid: 6620168
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1984;8(4-6):615-20
references.pmid: 6442439
references.citation: Ann N Y Acad Sci. 1992 Jun 28;654:431-3
references.pmid: 1632596
references.citation: J Pharmacol Exp Ther. 1984 Mar;228(3):691-5
references.pmid: 6707918
references.citation: Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):8966-71
references.pmid: 11459929
references.citation: Mol Pharmacol. 2011 Sep;80(3):416-25
references.pmid: 21670104
references.citation: J Pharmacol Exp Ther. 2008 May;325(2):629-40
references.pmid: 18310473
references.citation: BMC Evol Biol. 2010 Feb 18;10:51
references.pmid: 20167089
references.citation: Brain Res. 1982 Jul 8;243(1):107-17
references.pmid: 7116146
references.citation: Nature. 2005 Dec 8;438(7069):854-7
references.pmid: 16341013